US Patent Issued to The Regents of the University of California on Dec. 30 for "Determining the risk of opioid-related adverse events based on pupillary measurements" (California Inventors)

ALEXANDRIA, Va., Dec. 31 -- United States Patent no. 12,507,891, issued on Dec. 30, was assigned to The Regents of the University of California (Oakland, Calif.).

"Determining the risk of opioid-related adverse events based on pupillary measurements" was invented by Rachel Eshima McKay (San Francisco) and Merlin D. Larson (San Francisco).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides methods of managing opioid therapy, particularly, for pain management. The methods comprise determining in a subject, for example, a subject who has received an opioid treatment, pupillary unrest in ambient light (PUAL). Low values of PUAL can be used to identify patients at risk for opioid side-effects, s...